Literature DB >> 19495763

[Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors].

L-C Horn1, M Dallacker, K Bilek.   

Abstract

Malignant mixed Mullerian tumors (MMMT; carcinosarcomas) are rare epithelial-mesenchymal tumors. With an overall survival rate of 30%-40% the prognosis is much worse compared to high grade endometrioid or serous/clear cell carcinomas. Depending on the histology of the mensenchymal components a distinction is made between homologous and heterologous MMMT. Clinical, morphologic and molecular data suggest that MMMTs are really metaplastic carcinomas in which the mesenchymal part retains epithelial features. The strongest prognostic factor is tumor stage followed by lymph node metastases, deep myometrial infiltration, involvement of the cervix and tumor size. The distinction between homologous and heterologous MMMT is prognostically insignificant. Due to unreliable clinical staging and a high rate of occult lymph node metastases, the pathological-anatomical work-up is of great importance. Clinical and pathologic staging should be performed as in endometrial carcinoma. The main differential diagnoses include uterine sarcomas, adenosarcoma and benign metaplastic change within the endometrium.

Entities:  

Mesh:

Year:  2009        PMID: 19495763     DOI: 10.1007/s00292-009-1153-0

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  10 in total

Review 1.  Rare uterine cancers.

Authors:  Sheetal Acharya; Martee L Hensley; Anthony C Montag; Gini F Fleming
Journal:  Lancet Oncol       Date:  2005-12       Impact factor: 41.316

2.  Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.

Authors:  Ami P Vaidya; Neil S Horowitz; Esther Oliva; Elkan F Halpern; Linda R Duska
Journal:  Gynecol Oncol       Date:  2006-06-23       Impact factor: 5.482

3.  Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study.

Authors:  B Bodner-Adler; K Bodner; A Obermair; K Czerwenka; E Petru; S Leodolter; K Mayerhofer
Journal:  Anticancer Res       Date:  2001 Jul-Aug       Impact factor: 2.480

4.  Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus.

Authors:  S D Yamada; R A Burger; W R Brewster; D Anton; M F Kohler; B J Monk
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

Review 5.  Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

6.  Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.

Authors:  Frederic Amant; Isabelle Cadron; Luca Fuso; Patrick Berteloot; Eric de Jonge; Gerd Jacomen; Johan Van Robaeys; Patrick Neven; Philippe Moerman; Ignace Vergote
Journal:  Gynecol Oncol       Date:  2005-08       Impact factor: 5.482

7.  An evaluation of prognostic factors in uterine carcinosarcoma.

Authors:  R R Nordal; G B Kristensen; A E Stenwig; J M Nesland; E O Pettersen; C G Trope
Journal:  Gynecol Oncol       Date:  1997-12       Impact factor: 5.482

8.  Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases.

Authors:  S G Silverberg; F J Major; J A Blessing; B Fetter; F B Askin; S Y Liao; A Miller
Journal:  Int J Gynecol Pathol       Date:  1990       Impact factor: 2.762

9.  Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas.

Authors:  Jeffrey D Seidman; Suman Chauhan
Journal:  Int J Gynecol Pathol       Date:  2003-01       Impact factor: 2.762

10.  Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.

Authors:  Michael Callister; Lois M Ramondetta; Anuja Jhingran; Thomas W Burke; Patricia J Eifel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

  10 in total
  6 in total

1.  [New FIGO staging for uterine sarcomas].

Authors:  L-C Horn; D Schmidt; C Fathke; U Ulrich
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

2.  [Complex space-occupying lesion of the lesser pelvis].

Authors:  C Schäcke; A Panzner; A Kovács; M Simon; J Barkhausen
Journal:  Radiologe       Date:  2013-02       Impact factor: 0.635

3.  [Changes in the TNM classification of gynecological tumors].

Authors:  L-C Horn; M W Beckmann; A Beller; D Schmidt; U Ulrich; P Hantschmann; C Wittekind
Journal:  Pathologe       Date:  2010-09       Impact factor: 1.011

Review 4.  [Current TNM/FIGO classification for cervical and endometrial cancer as well as malignant mixed müllerian tumors. Facts and background].

Authors:  L-C Horn; K Schierle; D Schmidt; U Ulrich; A Liebmann; C Wittekind
Journal:  Pathologe       Date:  2011-05       Impact factor: 1.011

5.  Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015).

Authors:  D Denschlag; F C Thiel; S Ackermann; P Harter; I Juhasz-Boess; P Mallmann; H-G Strauss; U Ulrich; L-C Horn; D Schmidt; D Vordermark; T Vogl; P Reichardt; P Gaß; M Gebhardt; M W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-10       Impact factor: 2.915

Review 6.  [Grading of gynecological tumors : Current aspects].

Authors:  L-C Horn; D Mayr; C E Brambs; J Einenkel; I Sändig; K Schierle
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.